4/26
10:45 am
bgne
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report [Yahoo! Finance]
Low
Report
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report [Yahoo! Finance]
4/26
10:34 am
bgne
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
Low
Report
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
4/24
04:14 pm
bgne
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting [Yahoo! Finance]
Medium
Report
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting [Yahoo! Finance]
4/24
04:01 pm
bgne
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
Medium
Report
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
4/24
01:38 pm
bgne
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $235.00 to $236.00. They now have a "buy" rating on the stock.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $235.00 to $236.00. They now have a "buy" rating on the stock.
4/23
10:19 am
bgne
With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners [Yahoo! Finance]
Low
Report
With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners [Yahoo! Finance]
4/23
06:10 am
bgne
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer [Yahoo! Finance]
Medium
Report
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer [Yahoo! Finance]
4/23
06:00 am
bgne
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Medium
Report
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
4/8
01:18 pm
bgne
BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Bank of America Co. from $179.30 to $164.30. They now have a "neutral" rating on the stock.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Bank of America Co. from $179.30 to $164.30. They now have a "neutral" rating on the stock.
3/27
08:53 am
bgne
Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week [Yahoo! Finance]
Medium
Report
Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week [Yahoo! Finance]
3/27
08:09 am
bgne
BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Sanford C. Bernstein from $196.00 to $161.00. They now have a "market perform" rating on the stock.
Medium
Report
BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Sanford C. Bernstein from $196.00 to $161.00. They now have a "market perform" rating on the stock.
3/20
10:37 am
bgne
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $184.00 to $186.00. They now have an "overweight" rating on the stock.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $184.00 to $186.00. They now have an "overweight" rating on the stock.
3/14
04:40 pm
bgne
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy [Yahoo! Finance]
Low
Report
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy [Yahoo! Finance]
3/14
04:28 pm
bgne
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
Neutral
Report
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
3/14
10:30 am
bgne
Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials [Yahoo! Finance]
Low
Report
Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials [Yahoo! Finance]
3/14
10:12 am
bgne
Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
Low
Report
Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
3/13
08:00 am
bgne
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
Medium
Report
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
3/8
03:07 pm
bgne
FDA Roundup: March 8, 2024 [Yahoo! Finance]
Low
Report
FDA Roundup: March 8, 2024 [Yahoo! Finance]
3/7
05:35 pm
bgne
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
Medium
Report
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
3/7
05:19 pm
bgne
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Medium
Report
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
3/6
06:14 am
bgne
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 [Yahoo! Finance]
Medium
Report
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 [Yahoo! Finance]
3/6
06:00 am
bgne
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
Medium
Report
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
2/29
10:12 am
bgne
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [Yahoo! Finance]
Low
Report
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [Yahoo! Finance]
2/29
10:00 am
bgne
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Low
Report
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
2/28
08:05 am
bgne
BeiGene to Present at Upcoming Investor Conferences
Low
Report
BeiGene to Present at Upcoming Investor Conferences